Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M, Lister TA, Merlini G, Morel P, Stone M, Branagan AR, Leblond V. Kyle RA, et al. Among authors: leblond v. Semin Oncol. 2003 Apr;30(2):116-20. doi: 10.1053/sonc.2003.50038. Semin Oncol. 2003. PMID: 12720119 Review.
How we treat Waldenström's macroglobulinemia.
Dimopoulos MA, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. Dimopoulos MA, et al. Among authors: leblond v. Haematologica. 2005 Jan;90(1):117-25. Haematologica. 2005. PMID: 15642678 Review.
Transplantation in Waldenstrom's macroglobulinemia--the French experience.
Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, Cazin B, Divine M, Dreyfus B, Cahn JY, Pignon B, Desablens B, Perrier JF, Bay JO, Travade P. Tournilhac O, et al. Among authors: leblond v. Semin Oncol. 2003 Apr;30(2):291-6. doi: 10.1053/sonc.2003.50048. Semin Oncol. 2003. PMID: 12720155
Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel JP, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N. Leblond V, et al. J Clin Oncol. 1998 Jun;16(6):2060-4. doi: 10.1200/JCO.1998.16.6.2060. J Clin Oncol. 1998. PMID: 9626204
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. Among authors: leblond v. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
How to manage Waldenstrom's macroglobulinemia.
Buske C, Leblond V. Buske C, et al. Among authors: leblond v. Leukemia. 2013 Apr;27(4):762-72. doi: 10.1038/leu.2013.36. Epub 2013 Feb 6. Leukemia. 2013. PMID: 23385376 Free PMC article. Review.
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study.
Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH; EBMT Lymphoma Working Party. Montoto S, et al. Among authors: leblond v. Leukemia. 2007 Nov;21(11):2324-31. doi: 10.1038/sj.leu.2404850. Epub 2007 Jul 19. Leukemia. 2007. PMID: 17637813
416 results